



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Philip A. COLE, et al.

Serial No. 09/811,870

Filed: March 21, 2001

For: BISUBSTRATE INHIBITORS OF  
KINASES

Group Art Unit: 1645

Examiner: TBA

Attorney Docket No. 01107.00108

TECH CENTER 1600/2900

MAR 21 2002

RECEIVED

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to their duty of good faith and candor as set forth in 37 C.F.R. § 1.56(a)

Applicants submit herewith copies of documents cited on the attached Form PTO 1449.

Applicants respectfully request that the Examiner consider and enter these documents into the file of the above-identified application. No fee is believed to be due to ensure consideration and entry of the cited documents by the Examiner. However, if a fee is deemed necessary, the Commissioner is authorized to charge our Deposit Account No. 19-0733.


Date: March 20, 2002

Respectfully submitted,

By: Sarah A. Kagan

Sarah A. Kagan  
Reg. No. 32,141

BANNER & WITCOFF, LTD  
1001 G Street, N.W.  
Eleventh Floor  
Washington, D.C. 20001-4597  
(202) 508-9100



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	09/811,870
		Filing Date	March 21, 2001
		First Named Inventor	Philip A. COLE et al.
		Group Art Unit	1645
(use as many sheets as necessary)		Examiner Name	TBA
Sheet	1 of 1	Attorney Docket Number	001107.00108

RECEIVED  
MAR 21 2002  
FBI CENTER 1600/2900RECEIVED  
MAR 21 2002

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		RICOUART; "Design of Potent Protein Kinase Inhibitors Using the Bisubstrate approach"; Journal of Medical Chemistry, American Chemical Society; Vol. 34, No. 1, 1991, pp. 73 - 78.	
		S. R. HUBBARD; "Crystal Structure of the Activated Insulin Receptor Tyrosine Kinase in Complex with Peptide Substrate and ATP Analog"; The EMBO Journal, Vol. 16, No. 18, 1997, pp. 5572 - 5581.	
		MILLER, "Double Trouble"; Nature Structural Biology; Vol. 8, No. 1, January 2001, pp. 16 - 18.	
		E.A. PARANG; "Mechanism-Based Design of a Protein Kinase Inhibitor"; Nature Structural Biology, Vol. 8, No. 1, January 2002, pp. 37 - 41.	
		DENES MEDZIHRADSKY et al., "Solid-Phase Synthesis of Adenosine Phosphopeptides as Potential Bisubstrate Inhibitors of Protein Kinases", Journal of the American Chemical Society; Vol. 116, No. 21, 1994, pp. 9413 - 9419.	
		GÉRARD ROSSE et al., "Synthesis of Modified Tripeptides and Tetrapeptides as Potential Bisubstrate Inhibitors of the Epidermal Growth Factor Receptor Protein Tyrosine Kinase", Helvetica Chimica ACTA, (1997), 80(3), pp. 653 - 670.	
		E. A. KIM, "Kinetic Analysis of a Protein Tyrosine Kinase Reaction Transition State in the Forward and Reverse Directions", Journal of the American Chemical Society, Vol. 120, No. 28, July 1998, pp. 6851 - 6858.	
		International Search Report	

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.